☆ 4.7 Article

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies

LANCET INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.
Article Cell Biology

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

Izumi Kimura et al.

Summary: This study reveals the increased infectivity and antibody evasion mechanism of the SARS-CoV-2 Lambda variant using pseudoviruses. The spike protein of the Lambda variant is more infectious than other variants due to specific mutations, and the RSYLTPGD246-253N mutation is responsible for antibody evasion and enhanced infection.

CELL REPORTS (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Timothee Bruel et al.

Summary: There are differences in neutralizing activity of therapeutic antibodies against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, and immunocompromised individuals treated with antibodies show elevated antibody levels but reduced neutralization against Omicron. Breakthrough infections with the Omicron variant are observed in some immunocompromised individuals despite antibody treatment.

NATURE MEDICINE (2022)

Add to Collection
Letter Medicine, General & Internal

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Emi Takashita et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Immunology

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion

Isabella A. T. M. Ferreira et al.

Summary: The SARS-CoV-2 B.1.617 variant from India with key mutations L452R and E484Q shows reduced sensitivity to neutralizing antibodies elicited by the BNT162b2 mRNA vaccine, similar to the effect of L452R or E484Q mutations alone.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.